EM Vivas · Altitude illness
Altitude illness — AMS HACE HAPE and descent viva
Clinical viva on Lake Louise AMS, HACE ataxia, HAPE, descent, dexamethasone, nifedipine, acetazolamide.
On this page
Study tools
Target exams
Interpretation
Reveal interpretationShowHide
Three syndromes. Headache and malaise within six to twelve hours of ascent is acute mountain sickness; insomnia alone is not specific and was removed from the 2018 Lake Louise score.[9] Ataxia with altered consciousness suggests HACE. Dyspnoea with frothy sputum suggests HAPE.[3][4]
Definitive treatment. Descent is mandatory for cerebral and pulmonary oedema. HACE treatment emphasises descent and steroids.[4] HAPE needs immediate descent and/or adequate oxygen to maintain saturation above 90 per cent.[3][5]
Drugs. In an AMS trial, dexamethasone 8 mg initially then 4 mg every six hours reduced the score; the authors concluded it may facilitate safe descent.[7] Nifedipine is an adjunct for HAPE when descent and oxygen are unavailable.[6][5]
Prophylaxis. Slow ascent is most important.[3] Acetazolamide 125 mg twice daily reduced AMS.[8] A meta-analysis found 250 mg daily was the lowest effective dose.[10] For HAPE prophylaxis in susceptible people, nifedipine or tadalafil can be used for long sojourns and dexamethasone for a short stay of less than 5 days.[11]
References13ShowHide
- [1]Luks AM, Beidleman BA, Freer L, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 update. Wilderness & Environmental Medicine, 2024.PMID 37833187
- [2]Hackett PH, Roach RC. High-altitude illness. New England Journal of Medicine, 2001.PMID 11450659
- [3]Fiore DC, Hall S, Shoja P Altitude illness: risk factors, prevention, presentation, and treatment. American family physician, 2010.PMID 21121556
- [4]Hackett PH, Roach RC High altitude cerebral edema. High altitude medicine & biology, 2004.PMID 15265335
- [5]Stream JO, Grissom CK Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness & environmental medicine, 2008.PMID 19099331
- [6]Maggiorini M Prevention and treatment of high-altitude pulmonary edema. Progress in cardiovascular diseases, 2010.PMID 20417343
- [7]Ferrazzini G, Maggiorini M, Kriemler S, et al. Successful treatment of acute mountain sickness with dexamethasone. British medical journal (Clinical research ed.), 1987.PMID 3109663
- [8]Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High altitude medicine & biology, 2003.PMID 12713711
- [9]Roach RC, Hackett PH, Oelz O, et al. The 2018 Lake Louise Acute Mountain Sickness Score. High altitude medicine & biology, 2018.PMID 29583031
- [10]Low EV, Avery AJ, Gupta V, et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ (Clinical research ed.), 2012.PMID 23081689
- [11]Maggiorini M Prevention and treatment of high-altitude pulmonary edema. Progress in cardiovascular diseases, 2010.PMID 20417343
- [12]Bärtsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. The New England journal of medicine, 1991.PMID 1922223
- [13]Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Annals of internal medicine, 2006.PMID 17015867